CN114099639B - H1-pHSP65纳米疫苗及其制备方法和用途 - Google Patents
H1-pHSP65纳米疫苗及其制备方法和用途 Download PDFInfo
- Publication number
- CN114099639B CN114099639B CN202111416905.3A CN202111416905A CN114099639B CN 114099639 B CN114099639 B CN 114099639B CN 202111416905 A CN202111416905 A CN 202111416905A CN 114099639 B CN114099639 B CN 114099639B
- Authority
- CN
- China
- Prior art keywords
- phsp65
- nano
- vaccine
- hsp65
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000013612 plasmid Substances 0.000 claims abstract description 32
- 239000002539 nanocarrier Substances 0.000 claims abstract description 13
- 239000002105 nanoparticle Substances 0.000 claims abstract description 13
- 206010027476 Metastases Diseases 0.000 claims abstract description 10
- 230000009401 metastasis Effects 0.000 claims abstract description 8
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 6
- 101000944608 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Chaperonin GroEL 2 Proteins 0.000 claims abstract 6
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 7
- 102100037850 Interferon gamma Human genes 0.000 claims description 5
- 108010074328 Interferon-gamma Proteins 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 238000010276 construction Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 19
- 241000699670 Mus sp. Species 0.000 abstract description 13
- 239000002246 antineoplastic agent Substances 0.000 abstract description 6
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 230000028993 immune response Effects 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 102000006303 Chaperonin 60 Human genes 0.000 description 4
- 108010058432 Chaperonin 60 Proteins 0.000 description 4
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101000738180 Euglena gracilis Chaperonin CPN60, mitochondrial Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000025563 intercellular transport Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nanotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及疫苗制备技术领域,具体公开了H1‑pHSP65纳米疫苗及其制备方法和用途,通过pHSP65质粒的构建,进一步制备获得H1‑pHSP65纳米疫苗,具体是将H1纳米载体包裹HSP65质粒DNA形成H1‑pHSP65纳米颗粒。本发明制备的H1‑pHSP65纳米颗粒能够用于制备抗肿瘤药物,能够抑制肿瘤细胞的增殖和转移,能够有效激发小鼠的肿瘤免疫反应。
Description
技术领域
本发明属于疫苗制备技术领域,具体涉及H1-pHSP65纳米疫苗及其制备方法和用途。
背景技术
DNA疫苗在肿瘤疫苗中占有重要地位,是近年研究的热点之一。肿瘤DNA疫苗是利用基因工程技术将肿瘤相关抗原的基因负载到质粒载体上,借助载体或者人体基因表达系统,能持续引起较强的体液免疫和细胞免疫,达到预防和治疗疾病的目的。
HSP65(heat shock protein 65kD)是来源于卡介苗的热休克蛋白,是卡介苗的主要抗原之一,国际基因库登录号是M17705。卡介苗早在60年代即通过BCG膀胱内灌注用于浅表性膀胱癌的临床治疗,不仅可消灭原位癌,还可以预防肿瘤复发。但是,BCG的成分复杂,会引起一系列的毒副作用。许多肿瘤会过量表达和分泌HSP60蛋白,HSP60与肿瘤的发生、发展、转移有关,可以作为肿瘤靶标之一,但是内源性HSP60的免疫原性较差。HSP65是HSP60家族成员,与HSP60具有高度同源性(高于55%)。HSP65具有多重的T表位和B表位,具有强免疫原性,能刺激机体同时产生体液免疫和细胞免疫。
但是,核酸分子量较大、带负电等性质导致裸露DNA很难自主进入细胞,并且体内易降解,不能有效突破内皮细胞在血管腔内形成屏障,不能进入血管外的免疫细胞,从而阻碍特异性免疫反应的诱导。
纳米载体H1(PEI600-CyD-FA)是将阳离子聚合物聚乙烯亚胺PEI600通过环糊精CyD修饰和偶合叶酸FA配体修饰后得到的新型纳米复合物。H1不仅具有低毒、低免疫原性、水溶性好、生物相容性好的特点,可与带负电荷的细胞膜或质粒DNA通过静电天然吸附,具有增强细胞黏附吸收作用,促进胞间运输、缓释、基因转染效率高等多种良好特性;还能引起高水平的DC对抗原的摄取作用和更强的抗原交叉递呈作用,能显著提高抗原特异性CTL活性,增强抗原特异性的体液免疫及细胞免疫应答。由于H1具有DNA结合能力强、载体转染效率高、基因表达能力高、安全低毒等特点,适合作为基因疫苗的递呈载体。
发明内容
本发明的目的是提供了H1-pHSP65纳米疫苗及其制备方法和用途,通过热休克蛋白65/HSP65(国际基因库登录号是M17705)的基因联合H1(PEI600-CyD-FA)纳米载体构建获得H1-pHSP65纳米疫苗,制备得到的H1-pHSP65纳米疫苗能够用于制备抗肿瘤药物,能够更有效的被机体吸收,增强其免疫原性。
本发明提供了H1-pHSP65纳米疫苗的制备方法,具体包括如下步骤:
S1,pHSP65质粒的构建:根据HSP65序列设计引物,扩增得HSP65序列,以pcDNA3.1为真核表达载体构建得pHSP65质粒;
S2,H1-pHSP65纳米疫苗的制备:将质粒pHSP65转化入DH5a大肠杆菌感受态细胞,培养后提取质粒,将pHSP65质粒和H1纳米载体分别溶于PBS,静置5分钟后混合,静置10分钟后即得H1-pHSP65纳米疫苗。
进一步地,S1中,所述引物包括F引物和R引物;
所述F引物的基因序列如SEQ ID NO.1所示;
所述R引物的基因序列如SEQ ID NO.2所示。
进一步地,S2中,质粒pHSP65转化入DH5a大肠杆菌感受态细胞后培养温度为37℃。
进一步地,S2中,H1-pHSP65基因纳米疫苗是将H1纳米载体包裹HSP65质粒DNA形成H1-pHSP65纳米颗粒。
本发明还提供了由上述方法制备得到的H1-pHSP65纳米疫苗。
本发明还提供了所述的H1-pHSP65纳米疫苗在制备抗肿瘤药物中的应用。
本发明还提供了包含上述H1-pHSP65纳米疫苗的疫苗注射剂。
本发明还提供了所述的疫苗注射剂在制备抗肿瘤药物中的应用。
进一步地,所述疫苗注射剂包括但不限于用于制备抗肾癌的药物。
与现有技术相比,本发明具有以下有益效果:
1、本发明通过将H1纳米载体包裹HSP65质粒DNA形成H1-pHSP65纳米颗粒,使之更有效的被机体吸收,增强其免疫原性,制备得到的H1-pHSP65纳米疫苗能够用于制备抗肿瘤药物,能够抑制肿瘤细胞的增殖和转移,能够有效激发小鼠的肿瘤免疫反应。
2、本发明制备得到的H1-pHSP65纳米疫苗能够用于制备预防和治疗肾癌等肿瘤的药物。
附图说明
图1为本发明中质粒pcDNA3.1-HSP65示意图;
图2为本发明中琼脂糖凝胶电泳显示质粒DNA经H1纳米颗粒包裹后的电泳行为;
其中,泳道1为未包裹的质粒DNA;泳道2-5,表示同样的质粒DNA经不同量的H1纳米颗粒荷载;1-5泳道的质粒:H1的荷载比分别是1:0,1:1,1:2,1:3,1:4;
图3为本发明中质粒DNA经H1纳米颗粒包裹后的颗粒大小;
图4为本发明中制备的H1-pHSP65基因纳米疫苗对于肾癌Renca的防治作用;
图5为本发明中HE染色检测对照组及实验组荷瘤小鼠的肺脏病理切片的肿瘤转移情况;
图6为本发明中ELISPOT实验检测免疫后小鼠脾脏淋巴细胞分泌IFN-γ的表达。
具体实施方式
下面结合附图和具体实施方式对本发明进行详细说明,但应当理解本发明的保护范围并不受具体实施方式的限制。下列实施例中未注明具体条件的试验方法,通常按照常规条件操作,由于不涉及发明点,故不对其步骤进行详细描述。
当实施例给出数值范围时,应理解,除非本发明另有说明,每个数值范围的两个端点以及两个端点之间任何一个数值均可选用。除非另外定义,本发明中使用的所有技术和科学术语与本技术领域技术人员通常理解的意义相同。除实施例中使用的具体方法、设备、材料外,根据本技术领域的技术人员对现有技术的掌握及本发明的记载,还可以使用与本发明实施例中所述的方法、设备、材料相似或等同的现有技术的任何方法、设备和材料来实现本发明。
本发明提供了H1-pHSP65纳米疫苗及其制备方法和用途,通过热休克蛋白65/HSP65(国际基因库登录号是M17705)的基因联合H1(PEI600-CyD-FA)纳米载体,将H1纳米载体包裹HSP65质粒DNA形成H1-pHSP65纳米颗粒,使之更有效的被机体吸收,增强其免疫原性,制备得到的H1-pHSP65纳米疫苗能够用于制备抗肿瘤药物,能够抑制肿瘤细胞的增殖和转移,能够有效激发小鼠的肿瘤免疫反应。
实施例1
热休克蛋白65/pHSP65(国际基因库登录号是M17705)
一、本实施例提供了H1-pHSP65纳米疫苗的制备方法,包括如下步骤:
S1,pHSP65质粒的构建:
根据HSP65序列设计上、下游引物,分别为F引物和R引物,以pET28a-HSP65质粒为模板进行扩增,所述F引物的核苷酸序列如SEQ ID NO.1所示,所述R引物的核苷酸序列如SEQ ID NO.2所示;
SEQ ID NO.1:
SEQ ID NO.2:
SEQ ID NO.1中双下划线表示NcoI酶切位点,SEQ ID NO.2中双下划线表示EcoRI酶切位点;
扩增反应体系为:质粒模板0.5μL、上下游引物各1μL、2x Master Mix 10μL、水7.5μL,总体积为20μL。扩增程序为:98℃3min;98℃15s、55℃5s、72℃8min,30cycles;72℃10min;4℃保存。
通过上述PCR反应获得HSP65的DNA序列、以pcDNA3.1为真核表达载体、NcoI和EcoRI为酶切位点、插入HSP65序列,构建表达质粒pcDNA3.1-HSP65并测序验证(即为pHSP65质粒)(图1)。
S2,H1-pHSP65基因纳米疫苗的制备:
将上述质粒pHSP65转化入DH5a大肠杆菌感受态细胞,37度震荡培养过夜后提取质粒,琼脂糖凝胶电泳检测纯度并用nanodrop仪器检测DNA浓度,将pHSP65质粒和H1纳米载体分别溶于PBS,静置5分钟后混合,静置10分钟后即得H1-pHSP65基因纳米疫苗(图2、图3)。经zeta sizer检测,该纳米颗粒的直径约为152nm(图3)。
二、本发明制备的H1-pHSP65纳米疫苗的功能验证
1、H1-pHSP65纳米疫苗的抗肿瘤作用
选取6-8周龄雌性BALB/c小鼠随机分组:对照组、H1-pHSP65实验组。每2周一次皮下免疫治疗,共4次。免疫结束后,收集对数生长期的Renca细胞,按5×105个细胞/只注入小鼠腹侧皮下建立小鼠皮下移植瘤模型,观察疫苗的抗肿瘤作用。荷瘤后3周处死小鼠,取血、瘤和内脏。
如图4所示,和对照组相比,H1-pHSP65免疫组的小鼠肿瘤明显较小,说明H1-pHSP65疫苗有利于抑制小鼠肿瘤细胞的增殖。
2、HE染色检测荷瘤小鼠病理切片的肿瘤肺转移情况
处死小鼠,取肺脏于10%甲醛溶液中固定,石蜡包埋,4μm厚切片,HE染色,在光学显微镜下观察并拍照(10x)。
如图5所示,对照组的肺泡中有大量的肿瘤转移灶,H1-pHSP65实验组的小鼠肺脏的肿瘤转移灶较少,说明H1-pHSP65疫苗有利于抑制小鼠肿瘤细胞的转移,减少扩散。
3、ELISPOT实验检测脾脏淋巴细胞分泌IFN-γ的功能性T细胞
使用检测试剂盒(达优mouse IFN-γ2210005,达科为)中经IFN-γ抗体预包被的96孔板,RPMI-1640培养基200mL/孔封闭5-10min;分离小鼠脾细胞,105/孔接种于ELISPOT板;加入刺激物后,37℃、5%CO2培养箱培养3d。倾倒孔内细胞和培养基,加入预冷的去离子水200μL/孔,4℃放置10min;甩去孔内液体,洗板6次,每次在吸水纸上扣干;加入生物素标记的抗体工作液,37℃孵育1h;洗板6次;加入酶标亲和素工作液,37℃孵育1h;洗板5次;弃去并扣干孔内液体;加入AEC显色液,室温避光静置5-30min;倾倒孔内液体,揭开底座,洗涤3-5遍,终止显色;室温阴凉处晾干后读板。
如图6所示,H1-pHSP65免疫可以有效激发小鼠的Th1细胞免疫反应,促进IFN-γ的表达。
尽管已描述了本发明的优选实施例,但本领域内的技术人员一旦得知了基本创造性概念,则可对这些实施例作出另外的变更和修改。所以,所附权利要求意欲解释为包括优选实施例以及落入本发明范围的所有变更和修改。
显然,本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样,倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内,则本发明也意图包含这些改动和变型在内。
序列表
<110> 徐州医科大学
<120> H1-pHSP65纳米疫苗及其制备方法和用途
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 27
<212> DNA
<213> 人工合成
<400> 1
ccaccatggc caagacaatt gcgtacg 27
<210> 2
<211> 27
<212> DNA
<213> 人工合成
<400> 2
gcagaattct cagaaatcca tgccacc 27
Claims (1)
1.疫苗注射剂在制备抗肾癌药物中的应用,其特征在于,所述疫苗注射剂包括H1-pHSP65纳米疫苗,所述H1-pHSP65纳米疫苗制备过程包括如下步骤:
S1,pHSP65质粒的构建:根据HSP65序列设计引物,以pET28a-HSP65质粒为模板扩增得HSP65序列,以pcDNA3.1为真核表达载体,NcoI和EcoRI为酶切位点、插入HSP65序列,构建得pHSP65质粒;
所述引物包括F引物和R引物;
所述F引物的核苷酸序列如SEQ ID NO.1所示;
所述R引物的核苷酸序列如SEQ ID NO.2所示;
S2,H1-pHSP65纳米疫苗的制备:将质粒pHSP65转化入DH5a大肠杆菌感受态细胞,37℃培养后提取质粒,将pHSP65质粒和H1纳米载体分别溶于PBS,静置5分钟后混合,静置10分钟后即得H1-pHSP65纳米疫苗;
H1-pHSP65基因纳米疫苗是将H1纳米载体包裹HSP65质粒DNA形成H1-pHSP65纳米颗粒;
所述H1-pHSP65纳米颗粒免疫效果增强,有利于抑制肿瘤细胞的转移,减少扩散,促进IFN-γ的表达;
所述HSP65序列来源于卡介苗。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111416905.3A CN114099639B (zh) | 2021-11-25 | 2021-11-25 | H1-pHSP65纳米疫苗及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111416905.3A CN114099639B (zh) | 2021-11-25 | 2021-11-25 | H1-pHSP65纳米疫苗及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114099639A CN114099639A (zh) | 2022-03-01 |
CN114099639B true CN114099639B (zh) | 2024-03-01 |
Family
ID=80373393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111416905.3A Active CN114099639B (zh) | 2021-11-25 | 2021-11-25 | H1-pHSP65纳米疫苗及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114099639B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1517437A (zh) * | 2003-01-15 | 2004-08-04 | 张聪慧 | 特异性治疗肿瘤或胞内感染的疫苗及应用 |
CN1630819A (zh) * | 2001-04-03 | 2005-06-22 | 默克专利有限公司 | 肾细胞癌肿瘤标记 |
CN101338318A (zh) * | 2008-01-25 | 2009-01-07 | 林李家宓 | 一种聚阳离子转基因载体及其合成方法 |
CN102038958A (zh) * | 2009-10-19 | 2011-05-04 | 姚宏 | 一种纳米粒子组合物及其应用 |
CN102512683A (zh) * | 2011-12-26 | 2012-06-27 | 中山大学 | 一种高分子基因药物载体及其制备方法和在制备抗肿瘤药物中的应用 |
CN105031648A (zh) * | 2015-08-25 | 2015-11-11 | 徐州医学院 | 新型靶向纳米粒子及其制备方法和用途 |
CN108210482A (zh) * | 2016-12-09 | 2018-06-29 | 中国科学院深圳先进技术研究院 | 一种载miRNA复合纳米颗粒及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1572933A4 (en) * | 2002-02-13 | 2007-09-05 | Univ Duke | MODULATION OF IMMUNE RESPONSE BY POLYPEPTIDES OF RESPONSE TO STRESS BINDING TO NON PEPTIDES |
-
2021
- 2021-11-25 CN CN202111416905.3A patent/CN114099639B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1630819A (zh) * | 2001-04-03 | 2005-06-22 | 默克专利有限公司 | 肾细胞癌肿瘤标记 |
CN1517437A (zh) * | 2003-01-15 | 2004-08-04 | 张聪慧 | 特异性治疗肿瘤或胞内感染的疫苗及应用 |
CN101338318A (zh) * | 2008-01-25 | 2009-01-07 | 林李家宓 | 一种聚阳离子转基因载体及其合成方法 |
CN102038958A (zh) * | 2009-10-19 | 2011-05-04 | 姚宏 | 一种纳米粒子组合物及其应用 |
CN102512683A (zh) * | 2011-12-26 | 2012-06-27 | 中山大学 | 一种高分子基因药物载体及其制备方法和在制备抗肿瘤药物中的应用 |
CN105031648A (zh) * | 2015-08-25 | 2015-11-11 | 徐州医学院 | 新型靶向纳米粒子及其制备方法和用途 |
CN108210482A (zh) * | 2016-12-09 | 2018-06-29 | 中国科学院深圳先进技术研究院 | 一种载miRNA复合纳米颗粒及其制备方法和应用 |
Non-Patent Citations (10)
Title |
---|
Estela Noguera-Ortega and Esther Julián.《Mycobacterium - Research and Development》.2017,"Mycobacteria-Derived Agents for the Treatment of Urological and Renal CancersMycobacteria-Derived Agents for the Treatment of Urological and Renal Cancers". * |
Estela Noguera-Ortega et al..Mycobacteria-Based Vaccines as Immunotherapy for Non-urological Cancers.《Cancers (Basel)》.2020,文献号:1802. * |
Folate-mediated chemotherapy and diagnostics: an updated review and outlook;Leyuan Xu et al.;《J Control Release》;第 73–82页 * |
HSP60 silencing promotes Warburg-like phenotypes and switches the mitochondrial function from ATP production to biosynthesis in ccRCC cells;Ruifang Teng et al.;《Redox Biol.》;文献号:101218 * |
Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of CD8+ cells, interferon-gamma recovery and reduction of lung injury;V L D Bonato;《Immunology》;第130-138页 * |
Immune response to vaccination with DNA-hsp65 in a phase I clinical trial with head and neck cancer patients;G D Victora et al.;《Cancer Gene Therapy》;第598–608页 * |
Immunotherapeutic Activities of a DNA Plasmid Carrying the Mycobacterial hsp65 Gene (DNAhsp65);Celio Lopes Silva et al.;《Front Med Technol》;第2卷;摘要,第1页正文第3段,第7页左栏第3段 * |
Mycobacterium tuberculosis H37Rv, complete genome;NCBI Reference Sequence: NC_000962.3;《GenBank》;gene,ORIGIN段 * |
The gene transfection efficiency of a folate–PEI600–cyclodextrin nanopolymer;Hong Yao et al.;《Biomaterials.》;第30卷(第29期);摘要,第5794页右栏第2,8段,第5796页左栏第2段,第5797页右栏最后一段 * |
抗βhCG多表位融合蛋白疫苗治疗实验小鼠黑色素瘤的机制研究;杨洁 等;《药物生物技术》;第471-475页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114099639A (zh) | 2022-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Verbeke et al. | Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA | |
Xu et al. | Mannan-decorated pathogen-like polymeric nanoparticles as nanovaccine carriers for eliciting superior anticancer immunity | |
CN109568570B (zh) | 一种抗肿瘤疫苗复合物及制备方法、注射剂及应用 | |
Pan et al. | Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responses | |
CN109620956B (zh) | 一种智能巨噬细胞肿瘤靶向治疗系统及其制备方法和应用 | |
Huang et al. | Outer membrane vesicles (OMVs) enabled bio‐applications: A critical review | |
Persano et al. | Magnetic nanostructures as emerging therapeutic tools to boost anti-tumour immunity | |
CN111658782A (zh) | mRNA疫苗递送载体及制备方法、mRNA疫苗及制备方法 | |
Shao et al. | Phenylboronic acid-functionalized polyaminoglycoside as an effective CRISPR/Cas9 delivery system | |
Bagasariya et al. | Biomimetic nanotherapeutics: Employing nanoghosts to fight melanoma | |
Lv et al. | Multi-signaling pathway activation by pH responsive manganese particles for enhanced vaccination | |
Cui et al. | Bacteria-derived outer membrane vesicles engineered with over-expressed pre-miRNA as delivery nanocarriers for cancer therapy | |
Cui et al. | Targeted miR-34a delivery with PD1 displayed bacterial outer membrane vesicles-coated zeolitic imidazolate framework nanoparticles for enhanced tumor therapy | |
Fang et al. | Catalytic immunotherapy-photothermal therapy combination for melanoma by ferroptosis-activating vaccine based on artificial nanoenzyme | |
CN114099639B (zh) | H1-pHSP65纳米疫苗及其制备方法和用途 | |
CN113663060B (zh) | 全细胞肿瘤纳米疫苗、其制备方法和用途 | |
Du et al. | Targeting N6-methyladenosine reader YTHDF1 promotes second near-infrared Nano-Photothermal immunotherapy | |
Zhang et al. | Multi-functional extracellular vesicles: Potentials in cancer immunotherapy | |
Liu et al. | Manganese-based microcrystals equipped with Ythdf1-targeted biomimetic nanovaccines for reinforced dendritic cell spatiotemporal orchestration | |
CN116370618A (zh) | 一种全肿瘤细胞微载体支架疫苗及其制备方法 | |
CN104906567A (zh) | 一种配体介导的靶向树突状细胞的Texosomes仿生体作为肿瘤疫苗的应用 | |
CN102028958B (zh) | 以细菌纳米磁小体为载体的复合肿瘤基因疫苗及其制备方法 | |
KR19990063672A (ko) | 표적배향된 미립자물 유전 면역화에 의한 세포-매개 면역응답의 자극. | |
CN108186564B (zh) | 一种肿瘤微环境响应型基因纳米胶束及其制备方法和应用 | |
Li et al. | Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |